Sutro Biopharma To Present At The 44Th Annual J.P. Morgan Healthcare Conference

(MENAFN- GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Jane Chung, Chief Executive Officer, will present at the 44^th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 11:15 AM PT / 2:15 PM ET in San Francisco, CA.

A live webcast of the presentation will be accessible through the Events & Presentations page of the Investor Relations section of the Company's website at . An archived replay will be available for at least 30 days after the event.

About Sutro Biopharma
Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro's cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what's possible in cancer therapy. The Company's pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies. For more information, follow Sutro on social media @Sutrobio or visit .

Investor Contact:
Emily White
Sutro Biopharma
(650) 823-7681
...
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
...

MENAFN07012026004107003653ID1110569869